Biological Functions and Therapeutic Potential of SLC7A11 Across Diseases

Zhongping Ma; Qishan Ran

doi:10.54097/8907kw46

Authors

Zhongping Ma
Qishan Ran

DOI:

https://doi.org/10.54097/8907kw46

Keywords:

SLC7A11, System Xc⁻, Ferroptosis, Redox Homeostasis, Cancer Metabolism, Oxidative Stress, Disulfidptosis, Therapeutic Resistance, Exosome Delivery, Metabolic Reprogramming

Abstract

SLC7A11, a key component of the cystine/glutamate antiporter System Xc⁻, regulates redox balance and ferroptosis. Its dysregulation is linked to cancer, metabolic, neurodegenerative, immune, and kidney diseases. In tumors, SLC7A11 promotes growth and therapy resistance, while in non-cancerous tissues, it offers antioxidant protection. This review outlines the biological functions of SLC7A11, its dual disease roles, and therapeutic strategies including small molecule inhibitors, exosome delivery, and metabolic interventions. Though promising, clinical translation faces challenges in tissue specificity and metabolic compensation. Advances in precision targeting may help realize its full therapeutic potential.

Downloads

Download data is not yet available.

References

[1] Yan Y, Teng H, Hang Q, et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023 Jun 21;14(1):3673. doi: 10.1038/s41467-023-39401-9.

[2] Li Q, Guo G, Chen Y, et al. HCP5 Derived Novel Microprotein Triggers Progression of Gastric Cancer through Regulating Ferroptosis. Adv Sci (Weinh). 2024 Dec;11(46):e2407012. doi: 10. 1002/advs.202407012.

[3] Duan Y, Yan Y, Fu H, et al. SNHG15-mediated feedback loop interplays with HNRNPA1/SLC7A11/GPX4 pathway to promote gastric cancer progression. Cancer Sci. 2024 Jul;115 (7): 2269-2285. doi: 10.1111/cas.16181.

[4] He F, Zhang P, Liu J, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023 Aug;79(2):362-377. doi: 10.1016/j.jhep.2023.03.016.

[5] Zhan YF, Zhang J, Wang P. Changes and clinical significance of serum SLC7A11 in patients with hepatocellular carcinoma [J]. Chinese Hepatology, 2022, 27(12): 1288-1291.

[6] Hu N, Hu WH, Zhou SL, et al. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions. Neoplasma. 2021 Nov;68(6):1147-1156. doi: 10. 4149/ neo_2021_210327N410.

[7] Cao J, Zhou T, Wu T, et al. Targeting estrogen-regulated system xc- promotes ferroptosis and endocrine sensitivity of ER+ breast cancer. Cell Death Dis. 2025 Jan 20;16(1):30. doi: 10.1038/s41419-025-07354-0.

[8] Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021 Aug;12(8):599-620. doi: 10.1007/s13238-020-00789-5.

[9] Ke Y, Chen X, Su Y, et al. Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer via Inhibition of Cell Autophagy as a Competing Endogenous RNA. Front Oncol. 2021 Nov 1;11: 744940. doi: 10.3389/fonc.2021.744940.

[10] Lin F, Chen W, Zhou J, et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury. Cell Death Dis. 2022 Mar 26;13(3):271. doi: 10.1038/s41419-022-04708-w.

[11] Wang C, Liu H, Xu S, et al. Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cell Mol Neurobiol. 2023; 43:2627–2642. doi: 10.1007/s10571-023-01343-7.

[12] Luo C, Wu G, Xiao Z, et al. Role of miRNA regulation in IGFBP-2 overexpression and neuronal ferroptosis: Insights into the Nrf2/SLC7A11/GPX4 pathway in Alzheimer's disease. Int J Biol Macromol. 2025 Jan;287:138537. doi: 10.1016/j. ijbiomac.2024.138537.

[13] Shen Y, Wang Y, Liu F. Eupatilin mitigates ICH-induced brain injury via SOX2/SLC7A11 regulation of ferroptosis. Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 6. doi: 10.1007/ s00210-025-03928-z.

[14] Xiao F, Li HL, Yang B, et al. Disulfidptosis: A new type of cell death. Apoptosis. 2024; 29:1309–1329. doi: 10.1007/s10495-024-01989-8.

[15] Zhang W, Feng J, Ni Y, et al. The role of SLC7A11 in diabetic wound healing: novel insights and new therapeutic strategies. Front Immunol. 2024 Sep 3;15:1467531. doi: 10.3389/ fimmu. 2024.1467531.

[16] Shen J, Xie E, Shen S, et al. Essentiality of SLC7A11-mediated nonessential amino acids in MASLD. Sci Bull (Beijing). 2024 Dec 15;69(23):3700-3716. doi: 10.1016/j.scib.2024.09.019.

[17] Procaccini C, Garavelli S, Carbone F, et al. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity. 2021 Jul 13;54(7):1543-1560.e6. doi: 10.1016/j. immuni. 2021.04.014.

[18] Li Q, Guo G, Chen Y, et al. HCP5 Derived Novel Microprotein Triggers Progression of Gastric Cancer through Regulating Ferroptosis. Adv Sci (Weinh). 2024 Dec;11(46):e2407012. doi: 10. 1002/advs.202407012.

[19] Li Q, Zheng Y, Zhao J, et al. Radish red attenuates chronic kidney disease in obese mice through repressing oxidative stress and ferroptosis via Nrf2 signaling improvement. Int Immunopharmacol. 2024 Dec 25;143(Pt 3):113385. doi: 10.1016/j.intimp.2024.113385.

[20] Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022 May;12(5): e778. doi: 10.1002/ctm2.778.